{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T14:27:17Z","timestamp":1770474437609,"version":"3.49.0"},"reference-count":35,"publisher":"Impact Journals, LLC","issue":"47","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,11,22]]},"DOI":"10.18632\/oncotarget.12810","type":"journal-article","created":{"date-parts":[[2016,10,22]],"date-time":"2016-10-22T00:15:38Z","timestamp":1477095338000},"page":"76604-76612","source":"Crossref","is-referenced-by-count":84,"title":["Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy"],"prefix":"10.18632","volume":"7","author":[{"given":"Hyerim","family":"Ha","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ah-Rong","family":"Nam","sequence":"additional","affiliation":[{"name":"Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju-Hee","family":"Bang","sequence":"additional","affiliation":[{"name":"Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Eun","family":"Park","sequence":"additional","affiliation":[{"name":"Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae-Yong","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung-Hun","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea"},{"name":"Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sae-Won","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea"},{"name":"Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seock-Ah","family":"Im","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea"},{"name":"Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae-You","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea"},{"name":"Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yung-Jue","family":"Bang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea"},{"name":"Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Do-Youn","family":"Oh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea"},{"name":"Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2016,10,21]]},"reference":[{"issue":"6","key":"1","first-page":"djv048","article-title":"Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race\/Ethnicity, Poverty, and State","volume":"107","author":"Noone","year":"2015","journal-title":"Journal of the National Cancer Institute"},{"issue":"11","key":"2","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1038\/sj.bjc.6605063","article-title":"Viral hepatitis-associated intrahepatic cholangiocarcinoma shares common disease processes with hepatocellular carcinoma","volume":"100","author":"Hsieh","year":"2009","journal-title":"British journal of cancer"},{"issue":"1","key":"3","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/hep.22606","article-title":"Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of US veterans","volume":"49","author":"Giordano","year":"2009","journal-title":"Hepatology"},{"issue":"suppl 4","key":"4","doi-asserted-by":"crossref","first-page":"S308","DOI":"10.1093\/annonc\/10.suppl_4.S308","article-title":"Risk factors for biliary tract carcinogenesis","volume":"10","author":"Chapman","year":"1999","journal-title":"Annals of oncology"},{"issue":"5","key":"5","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Weinberg","year":"2011","journal-title":"cell"},{"issue":"10","key":"6","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1002\/eji.201242590","article-title":"Autoimmunity-mediated antitumor immunity: Tumor as an immunoprivileged self","volume":"42","author":"Chen","year":"2012","journal-title":"European journal of immunology"},{"issue":"7","key":"7","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S1470-2045(12)70209-7","article-title":"Circulating tumour cells in non-metastatic breast cancer: a prospective study","volume":"13","author":"Krishnamurthy","year":"2012","journal-title":"The lancet oncology"},{"issue":"10","key":"8","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1158\/0008-5472.CAN-11-3733","article-title":"Real-time monitoring of rare circulating hepatocellular carcinoma cells in an orthotopic model byflow cytometry assesses resection on metastasis","volume":"72","author":"Wei","year":"2012","journal-title":"Cancer research"},{"issue":"26","key":"9","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumabipilimumab in advanced melanoma","volume":"372","author":"Lotem","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"21","key":"10","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Horn","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"11","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/CJI.0b013e318156e47e","article-title":"Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis","volume":"30","author":"Mavroukakis","year":"2007","journal-title":"Journal of immunotherapy (Hagerstown, Md: 1997)"},{"issue":"19","key":"12","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1158\/1078-0432.CCR-13-0143","article-title":"CTLA-4 and PD-1\/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients","volume":"19","author":"Robert","year":"2013","journal-title":"Clinical Cancer Research"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Nakamura, Arai, Totoki, Shirota, Elzawahry, Kato, Hama, Hosoda, Urushidate, Ohashi. Genomic spectra of biliary tract cancer. Nature genetics. 2015.","DOI":"10.1038\/ng.3375"},{"issue":"3","key":"14","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00262-010-0960-8","article-title":"Immunologic biomarkers as correlates of clinical response to cancer immunotherapy","volume":"60","author":"Disis","year":"2011","journal-title":"Cancer immunology, immunotherapy"},{"issue":"13","key":"15","doi-asserted-by":"crossref","first-page":"5326","DOI":"10.1158\/0008-5472.CAN-09-3879","article-title":"Wnt inhibitor Dickkopf-1 as a target for passive cancer immunotherapy","volume":"70","author":"Miyamoto","year":"2010","journal-title":"Cancer research"},{"issue":"19","key":"16","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy","volume":"20","author":"Anders","year":"2014","journal-title":"Clinical Cancer Research"},{"issue":"3","key":"17","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1158\/1078-0432.CCR-08-1608","article-title":"Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma","volume":"15","author":"Xiao","year":"2009","journal-title":"Clinical Cancer Research"},{"issue":"7","key":"18","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1002\/cncr.24899","article-title":"Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma","volume":"116","author":"Tokura","year":"2010","journal-title":"Cancer"},{"issue":"7","key":"19","doi-asserted-by":"publisher","first-page":"5449","DOI":"10.18632\/oncotarget.3216","article-title":"Prognostic and predictive value of PDL1 expression in breast cancer","volume":"6","author":"Bertucci","year":"2015","journal-title":"Oncotarget"},{"issue":"5","key":"20","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/intimm\/8.5.765","article-title":"Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes","volume":"8","author":"Honjo","year":"1996","journal-title":"International immunology"},{"issue":"8","key":"21","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Tamada","year":"2002","journal-title":"Nature medicine"},{"key":"22","unstructured":"Postow, Callahan, Wolchok. Immune checkpoint blockade in cancer therapy. Journal of Clinical Oncology. 2015:JCO. 2014.2059. 4358."},{"issue":"6","key":"23","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nri2326","article-title":"Inhibitory B7-family molecules in the tumour microenvironment","volume":"8","author":"Chen","year":"2008","journal-title":"Nature Reviews Immunology"},{"issue":"1","key":"24","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2326-6066.CIR-13-0034","article-title":"PD-L1 expression in the merkel cell carcinoma microenvironment: association with inflammation, merkel cell polyomavirus, and overall survival","volume":"1","author":"Sidransky","year":"2013","journal-title":"Cancer immunology research"},{"issue":"7","key":"25","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1158\/1078-0432.CCR-10-0250","article-title":"Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma","volume":"17","author":"Kwon","year":"2011","journal-title":"Clinical Cancer Research"},{"issue":"12","key":"26","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1038\/leu.2014.137","article-title":"High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial","volume":"28","author":"Lamy","year":"2014","journal-title":"Leukemia"},{"issue":"38","key":"27","doi-asserted-by":"publisher","first-page":"41228","DOI":"10.18632\/oncotarget.5682","article-title":"Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma","volume":"6","author":"Lu","year":"2015","journal-title":"Oncotarget"},{"issue":"2","key":"28","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.coi.2010.11.013","article-title":"Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment","volume":"23","author":"Kline","year":"2011","journal-title":"Current opinion in immunology"},{"issue":"7","key":"29","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s00262-011-1172-6","article-title":"An immune-active tumor microenvironment favors clinical response to ipilimumab","volume":"61","author":"Siemers","year":"2012","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"9","key":"30","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.ejca.2014.02.015","article-title":"Neutrophil\/lymphocyte ratio as a prognostic factor in biliary tract cancer","volume":"50","author":"Knox","year":"2014","journal-title":"European Journal of Cancer"},{"issue":"23","key":"31","doi-asserted-by":"crossref","first-page":"6212","DOI":"10.1158\/1078-0432.CCR-14-0442","article-title":"Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma","volume":"20","author":"Zhou","year":"2014","journal-title":"Clinical Cancer Research"},{"issue":"2","key":"32","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.pan.2014.12.004","article-title":"Clinical implications of systemic inflammatory response markers as independent prognostic factors for advanced pancreatic cancer","volume":"15","author":"Chen","year":"2015","journal-title":"Pancreatology"},{"key":"33","unstructured":"Hansen, Hurwitz, Madow. Sample Survey Methods and Theor. 1953."},{"key":"34","unstructured":"Williams. Finding optimal cutpoints for continuous covariates with binary and time-to-event outcomes. 2006."},{"issue":"20","key":"35","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1002\/(SICI)1097-0258(19961030)15:20<2203::AID-SIM357>3.0.CO;2-G","article-title":"A simulation study of cross-validation for selecting an optimal cutpoint in univariate survival analysis. Statistics in medicine","volume":"15","author":"Simon","year":"1996","journal-title":"Statistics in medicine"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.12810","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T12:58:03Z","timestamp":1596718683000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.12810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,21]]},"references-count":35,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2016,11,22]]}},"alternative-id":["12810","27780932"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.12810","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,21]]}}}